Cencora Surges 2.9% Pre-Market on Institutional Buying and M&A Optimism

Institutional Stakes Signal Confidence

Cencora (COR) is seeing a sharp 2.87% move in early trading ahead of the Tuesday open, a notable divergence from the S&P 500, which remains unchanged in the pre-market session. The primary driver for this morning's activity appears to be a wave of positive sentiment following new regulatory disclosures. Specifically, Daytona Street Capital LLC reported a significant new stake in the company, purchasing 40,000 shares valued at approximately $13.5 million. This position now accounts for roughly 9% of the firm's portfolio, signaling a high-conviction bet on the drug wholesaler's current valuation.

This institutional interest comes at a critical time for Cencora, which has seen its stock trade near the lower end of its 52-week range of $267.40 to $377.54. With institutional investors already owning over 97% of the float, the entry of new major players is providing a technical floor for the stock as it attempts to reclaim its 50-day moving average of $347.92.

Specialty Expansion via EyeSouth Acquisition

Beyond the technical buying, investors are increasingly optimistic about Cencora’s strategic pivot toward specialty pharmaceutical services. On March 23, the company signed a definitive $1.1 billion agreement to acquire the retina division of EyeSouth Partners. This deal is designed to expand Cencora’s 'Retina Consultants of America' platform, a key component of its high-margin specialty distribution strategy.

Analysts have noted that this acquisition is expected to be accretive to adjusted diluted earnings per share (EPS) within the first 12 months. By deepening its footprint in ophthalmology, Cencora is effectively diversifying away from the lower-margin core drug distribution business. This shift is a core reason why firms like Wells Fargo recently raised their price objective to $429.00, while the broader analyst consensus remains a 'Moderate Buy' with a target of $403.17—implying nearly 25% upside from current levels.

Pre-Earnings Momentum and Reaffirmed Guidance

Today’s pre-market surge also reflects a 'pre-earnings run' as investors look toward the company’s Second Quarter Fiscal 2026 results, scheduled for release on May 6. On April 1, Cencora officially set the date for the report, reminding the market of its robust financial targets. The company previously reaffirmed its full-year 2026 adjusted diluted EPS guidance range of $17.45 to $17.75, despite the upcoming retirement of long-time CFO James F. Cleary in June.

While the leadership transition initially caused some volatility, J.P. Morgan analyst Lisa Gill noted that Cleary’s decision to stay on in an advisory capacity through the end of 2026 should ensure continuity. As the market digests the impact of the OneOncology integration and the EyeSouth deal, Cencora appears to be regaining its status as a defensive favorite in a flat macro environment. Investors will be watching for any further updates on the $3.5 billion MWI Animal Health divestiture, which is expected to further sharpen the company's focus on human specialty health.